Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O60888

UPID:
CUTA_HUMAN

ALTERNATIVE NAMES:
Acetylcholinesterase-associated protein; Brain acetylcholinesterase putative membrane anchor

ALTERNATIVE UPACC:
O60888; A2AB26; A2BEL4; Q3B784; Q5JXM9; Q5SU05; Q9NYQ9

BACKGROUND:
The Protein CutA, identified by its alternative names such as Brain acetylcholinesterase putative membrane anchor, is implicated in forming a complex with membrane proteins attached to acetylcholinesterase (AChE). This relationship underscores its potential importance in neurotransmission and neural development.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Protein CutA offers a promising avenue for drug discovery, particularly in the realm of neurodegenerative diseases. By elucidating its role in acetylcholine regulation, novel approaches for enhancing cognitive function and treating diseases like Alzheimer's could emerge.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.